Lexaria Bioscience Corp. (LEXX)

NCM – Real Time Price. Currency in USD

0.58

-0.03 (-4.63%)

At close: May 12, 2026, 4:00 PM EDT

0.59

+0.02 (2.67%)

Pre-market: May 13, 2026, 7:53 AM EDT

07.05.2026

Lexaria Bioscience Releases Second Episode of Investor Video Series

CEO Rich Christopher Discusses Recently Announced Material Transfer Agreement Extension and 2026 Research Priorities Kelowna, British Columbia – May 7, 2026 - TheNewswire - Lexaria Bioscience Corp. (NASDAQ:LEXX) ("Lexaria" or the "Company"), a global innovator in oral drug delivery platforms, today released the second episode of Reformulated: Into the Mainstream , the Company's ongoing investor communications series.

01.05.2026

Lexaria Bioscience Launches Ongoing Investor Video Series to Expand Shareholder Communications

Inaugural Episode Features CEO Rich Christopher on DehydraTECH Platform, GLP-1 Market Opportunity and Commercial Strategy KELOWNA, BC / ACCESS Newswire / May 1, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) ("Lexaria" or the "Company"), a global innovator in oral drug delivery platforms, today announced the launch of Reformulated: Into the Mainstream, an ongoing investor communications series designed to support transparency, consistent engagement, and alignment with shareholders and the broader investment community. As Lexaria continues executing its strategy within the rapidly evolving GLP-1 and oral drug delivery landscape, the video series will feature regular interviews and management discussions with Lexaria leadership.

29.04.2026

Material Transfer Agreement Between Pharmaceutical Company and Lexaria is Extended

KELOWNA, BC / ACCESS Newswire / April 29, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) ("Lexaria" or the "Company"), a global innovator in oral drug delivery platforms, provides this update on the Material Transfer Agreement ("MTA") originally entered into on August 30, 2024 with a pharmaceutical company ("PharmaCO") to evaluate Lexaria's DehydraTECH™ technology in a pre-clinical setting. The original agreement has been successfully extended through December 31, 2026, to accommodate time required for PharmaCO's receipt and review of Lexaria's 2026 research & development ("R&D") results related to GLP-1.

23.04.2026

Lexaria Launches New Study to Examine Next-Generation GLP-1 Drugs

Contracts signed for Animal Study #2: GLP-1-A26-2 Amycretin and retatrutide to be tested for compatibility with DehydraTECH

23.04.2026

Lexaria Launches New Study to Examine Next-Generation GLP-1 Drugs

Contracts signed for Animal Study #2: GLP-1-A26-2 Amycretin and retatrutide to be tested for compatibility with DehydraTECH KELOWNA, BC / ACCESS Newswire / April 23, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX), (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is pleased to announce the engagement of the contract research organization ("CRO") to execute and report on its 2026 Animal Study #2 (GLP-1-A26-2) that will evaluate a number of formulation enhancements with two next-generation glucagon-like peptide-1 ("GLP-1") drugs in animals (the "Study") to explore the potential for improved DehydraTECH performance as well as potentially stake new intellectual property claims. Contracts with the CRO have been signed; Study design has been completed; formulation manufacturing is underway; and dosing is expected to begin within 30 days.

21.04.2026

Lexaria Expects Oral GLP-1 Pills to Generate Billions in New Industry Sales

600,000 New Wegovy® Pill Prescriptions Written in First Two Months KELOWNA, BC / ACCESS Newswire / April 21, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX), (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, provides this update of additional recent developments in the fast-moving glucagon-like peptide-1 ("GLP-1") oral (or "pill") market. The GLP-1 oral pill sector is growing much faster in 2026 than expected, and faster than the pre-existing GLP-1 injectable sector.

21.04.2026

Lexaria Expects Oral GLP-1 Pills to Generate Billions in New Industry Sales

600,000 New Wegovy® Pill Prescriptions Written in First Two Months Kelowna, British Columbia – April 21, 2026 - TheNewswire – Lexaria Bioscience Corp. (Nasdaq: LEXX), (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, provides this update of additional recent developments in the fast-moving glucagon-like peptide-1 (“GLP-1”) oral (or “pill”) market.

Videos

No Data

There is no data to display

Press releases

07.05.2026

Lexaria Bioscience Corp. (LEXX)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Lexaria Bioscience Corp. (LEXX)

Lexaria Bioscience Releases Second Episode of Investor Video Series

Lexaria Bioscience Launches Ongoing Investor Video Series to Expand Shareholder Communications

Material Transfer Agreement Between Pharmaceutical Company and Lexaria is Extended

Lexaria Launches New Study to Examine Next-Generation GLP-1 Drugs

Lexaria Launches New Study to Examine Next-Generation GLP-1 Drugs

Lexaria Expects Oral GLP-1 Pills to Generate Billions in New Industry Sales

Lexaria Expects Oral GLP-1 Pills to Generate Billions in New Industry Sales

Videos

No Data

Press releases

Lexaria Bioscience Releases Second Episode of Investor Video Series

Lexaria Bioscience Releases Second Episode of Investor Video Series

Lexaria Bioscience Launches Ongoing Investor Video Series to Expand Shareholder Communications

Material Transfer Agreement Between Pharmaceutical Company and Lexaria is Extended

Lexaria Launches New Study to Examine Next-Generation GLP-1 Drugs

Lexaria Launches New Study to Examine Next-Generation GLP-1 Drugs

Lexaria Expects Oral GLP-1 Pills to Generate Billions in New Industry Sales

Lexaria Expects Oral GLP-1 Pills to Generate Billions in New Industry Sales

Videos

No Data

Press releases

Lexaria Bioscience Releases Second Episode of Investor Video Series

Lexaria Bioscience Launches Ongoing Investor Video Series to Expand Shareholder Communications

Material Transfer Agreement Between Pharmaceutical Company and Lexaria is Extended

Lexaria Launches New Study to Examine Next-Generation GLP-1 Drugs

Search stocks

Lexaria Bioscience Corp. (LEXX)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Lexaria Bioscience Corp. (LEXX)

Lexaria Bioscience Releases Second Episode of Investor Video Series

Lexaria Bioscience Launches Ongoing Investor Video Series to Expand Shareholder Communications

Material Transfer Agreement Between Pharmaceutical Company and Lexaria is Extended

Lexaria Launches New Study to Examine Next-Generation GLP-1 Drugs

Lexaria Launches New Study to Examine Next-Generation GLP-1 Drugs

Lexaria Expects Oral GLP-1 Pills to Generate Billions in New Industry Sales

Lexaria Expects Oral GLP-1 Pills to Generate Billions in New Industry Sales

Videos

No Data

Press releases

Lexaria Bioscience Releases Second Episode of Investor Video Series

Lexaria Bioscience Releases Second Episode of Investor Video Series

Lexaria Bioscience Launches Ongoing Investor Video Series to Expand Shareholder Communications

Material Transfer Agreement Between Pharmaceutical Company and Lexaria is Extended

Lexaria Launches New Study to Examine Next-Generation GLP-1 Drugs

Lexaria Launches New Study to Examine Next-Generation GLP-1 Drugs

Lexaria Expects Oral GLP-1 Pills to Generate Billions in New Industry Sales

Lexaria Expects Oral GLP-1 Pills to Generate Billions in New Industry Sales

Videos

No Data

Press releases

Lexaria Bioscience Releases Second Episode of Investor Video Series

Lexaria Bioscience Launches Ongoing Investor Video Series to Expand Shareholder Communications

Material Transfer Agreement Between Pharmaceutical Company and Lexaria is Extended

Lexaria Launches New Study to Examine Next-Generation GLP-1 Drugs